Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: sam who wrote (4066)	4/16/1998 11:33:00 AM
From: Steve Fancy	Read Replies (2) \| Respond to of 6136

NEW YORK, April 16 (Reuters) - Morgan Stanley Dean Witter said it lowered its rating on Agouron Pharmaceuticals Inc. to outperform from strong buy. -- Despite continued excellent performance of the Viracept product, Morgan analyst Douglas Lind said in a research note that Agouron has not diversified top-line risk through licensing. -- The price target was lowered to $45 from $53. -- The shares still have significant upside potential. -- Agouron was off 1-7/16 at 35-1/16 in morning trading. Copyright 1998, Reuters News Service